Exicure, Inc. (XCUR) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 21, 2023, by Exicure, Inc., a Delaware corporation. The report details significant corporate governance changes, including the closing of a private placement, the appointment and resignation of board members, and notices received from The Nasdaq Stock Market LLC regarding listing compliance deficiencies.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses the following specific financial details:
- Private Placement: The Company closed a private placement on February 24, 2023, issuing 3,400,000 shares of common stock at $1.60 per share.
- Related Party Transactions: Approximately $465,000 has been paid or is payable to entities controlled by new board member Paul Kang for business development consulting services provided in 2022.
- Director Compensation: New directors Paul Kang, Hyukku Lee, and Changil Ahn are expected to receive an annual retainer of $20,000 each.
Material Changes Versus Prior Period
The filing highlights several material changes in corporate structure and governance status:
- Board Composition: Paul Kang, Hyukku Lee, and Changil Ahn were appointed to the Board effective February 24, 2023. Concurrently, Elizabeth Garofalo, M.D., resigned from the Board and all committee chairships effective February 24, 2023.
- Nasdaq Compliance Status: The Company received notice on February 21, 2023, of non-compliance with Nasdaq Listing Rule 5605 regarding compensation committee independence due to the prior resignation of Jeffrey L. Cleland, Ph.D. Additionally, the Company lost its cure period for non-compliance regarding independent director and audit committee requirements.
- Controlled Company Status: Following the private placement, the Company believes it is now eligible to rely on Nasdaq's controlled company exemption for the majority independence requirement.
Guidance, Outlook, Risks, and Contingencies
Management provided the following outlook and risk disclosures:
- Compliance Plan: The Company plans to submit a definitive plan to Nasdaq to regain compliance with listing rules. It has 45 calendar days to submit this plan, which could grant an extension of up to 180 days to evidence compliance.
- Exemptions: The Company intends to rely on the controlled company exemption for the majority independence requirement but is not exempt from and intends to regain compliance with the Audit Committee requirements.
- Risks: Forward-looking statements are subject to risks including the ability to regain Nasdaq compliance, eligibility for controlled company exemptions, and potential litigation related to the private placement or change in control.
Investor Verification Checklist
- Verify the final acceptance of the Company's compliance plan by Nasdaq and the specific timeline for regaining full listing status.
- Confirm the Company's continued eligibility for the "controlled company" exemption following the private placement.
- Review the impact of the resignation of Dr. Garofalo and the appointment of CBI designees on the independence of the Audit Committee.
- Monitor for any litigation risks associated with the private placement or the recent change in control.